clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
Published 1 year ago • 383 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
0:31
remaining questions regarding her2-low breast cancer
-
6:51
adcs for her2 and her2-low breast cancer
-
0:52
defining her2-low breast cancer as a clinical subtype
-
1:33
questions remaining in the field of her2-low breast cancer
-
4:11
what is her2 positive breast cancer? | treatment/therapies for her2 positive breast cancer
-
14:08
her2 amplification and breast cancer part 1
-
3:53
ki-67: explained!!! #medschooldiscussion
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
1:36
is her2-low a distinct subtype of breast cancer?
-
3:22
her2 blockade in her2-e induces low-proliferative luminal a phenotype
-
0:51
ember-2: preoperative imlunestrant for er /her2- early stage breast cancer
-
2:59
talent: neoadjuvant t-dxd with or without anastrozole for her2-low, hr early stage breast cancer
-
1:49
early breast cancer: do we need chemotherapy in low genomic/high clinical risk (er /her2-)?
-
1:22
genomic profiling in her2 disease
-
2:05
latest news in her2-low breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
1:29
takeaways on the management of early-stage tnbc